This regulation of FGFR3 by MYC seemed to be quite specific to bladder cancer, because MYC binding to the FGFR3 enhancers or promoter was rarely observed in a publicly available dataset encompassing 118 MYC chromatin immunoprecipitation and sequencing (ChIP‐Seq) in different tissues (Appendix Fig S5A). This evidence concerns the gene MYC and urinary bladder carcinoma.